GI
TSHA icon

GAMMA Investing’s Taysha Gene Therapies TSHA Stock Holding History

GAMMA Investing’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58K Buy
232
+97
+72% +$574 ﹤0.01% 3770
2026
Q1 		$603 Sell
135
-141
-51% -$656 ﹤0.01% 3919
2025
Q4 		$1.52K Buy
+276
New +$1.34K ﹤0.01% 3684

Other funds holding TSHA

AWM
Affinity Wealth Management Wilmington, Delaware $776M AUM 43.59% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
PFSRSONJ
Police & Firemen's Retirement System of New Jersey Trenton, New Jersey $13.3B AUM 45.46% 1-Year Est. Return
RRA
Red Reef Advisors Boca Raton, Florida $108M AUM
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return
WN
Williams & Novak Westlake Village, California $151M AUM 27.43% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
DJSG
D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return

GAMMA Investing's TSHA Position: Q2 2026 in Review

GAMMA Investing increased its Taysha Gene Therapies (TSHA) stake by 72% in Q2 2026, buying an estimated $574 and bringing the position to 232 shares worth $1.58K. The position accounts for ﹤0.01% of the portfolio, ranked #3770.

GAMMA Investing first reported a position in TSHA in Q4 2025 and has held it in 3 quarters since. 18 funds tracked by Wall St. Rank hold TSHA as of Q2 2026.

  • GAMMA Investing held 232 shares of Taysha Gene Therapies worth $1.58K as of Q2 2026.
  • GAMMA Investing bought 97 Taysha Gene Therapies shares in Q2 2026, an estimated $574.
  • Taysha Gene Therapies made up ﹤0.01% of GAMMA Investing's portfolio in Q2 2026, its #3770 holding.
  • GAMMA Investing first reported a position in Taysha Gene Therapies in Q4 2025 and has held it in 3 quarters since.
  • 18 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q2 2026.

Based on GAMMA Investing's 13F filing for Q2 2026, filed 7 Jul 2026.